Month: 2026 年 1 月

TOKYO, Jan 6, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) will exhibit at the Tokyo Auto Salon 2026, one of the world's largest custom car shows, to be held from January 9 until January 11 at Makuhari Messe in Chiba, Japan. A total of 11 vehicles will be on display, with the customized versions of the all-new Delica Mini super height-wagon kei-car* and the upgraded Delica D:5 minivan as the centerpiece.With the theme “Delica Festival — unleash your playful spirit,” Mitsubishi Motors sets the stage for a showcase with custom vehicles that highlight the strength and versatility of the Delica D:5 and Delica Mini. Adding to the excitement, the actual rally car that claimed overall victory at the Asia Cross Country Rally 2025 (AXCR 2025) and the Delica D:5 support car will also be on display.Visitors will be welcomed into a vibrant, Japanese-inspired festival setting complete with themed decorations. Appearances by Delimaru, the official mascot inspired by the Delica Mini, will bring the playful spirit of the “Delica Festival” to life as it greets guests throughout the booth. Delica Mini Delimaru FestaTo express the booth’s “Delica Festival” theme, this model is decorated with playful touches of decals and wraps featuring the beloved mascot, Delimaru. To match the lively, festive atmosphere of the booth, a giant Delimaru riding on the Delica Mini is also dressed in a traditional Japanese happi coat, bringing the festive spirit to life. Delica D:5 Ultimate GearThis model takes the toughness of the Delica D:5 to the next level, expressing the power to push forward even in harsh environments. With its body lifted by 30 millimeters (mm), it is fitted with bumper guards and side steps designed for rugged terrain. To complete the look, the entire vehicle features a special rugged textured coating that makes scratches less noticeable, creating a bold and off-road-ready Delica D:5. Delica Mini Ultimate GearSpecially prepared for Tokyo Auto Salon 2026, this Delica Mini features an exclusive two-tone finish, enhanced with a rugged textured coating for added boldness and toughness. Equipped with a roof rack, front grille guard, and rear ladder, along with a 20-mm suspension lift, this customized model embodies Mitsubishi Motors’ adventurous spirit — ready to tackle challenging terrain. Delica D:5 Active Camper Featuring a warm, white birch wood-grain finish paired with a soothing brown interior, this model is a collaboration with the outdoor brand LOGOS. It introduces a premium outdoor style while maintaining the versatility of the Delica D:5 and its 4WD capability, making it the perfect companion from everyday driving to weekend adventures. Delica Mini Active Camper This Delica Mini is equipped with a pop-up roof, a front skid bar, and mud flaps — customized to inspire outdoor adventures with friends. A lift kit of 25 mm enhances off-road capability, making this model a true companion for those who want to fully embrace the outdoor experience. Delica Mini x “DALI” with DAMD This original custom car — finished with accessories from DALI, a new brand by custom parts manufacturer DAMD Inc. — pays homage to the Pajero through its front grille and lights. While preserving Mitsubishi Motors’ signature profile, it blends retro charm with a cute yet rugged styling, catering to customers seeking a car that stands out and showcases uniqueness. Delica D:5 Wild Adventure style Equipped with genuine Mitsubishi Motors accessories, this model features exclusive enhancements for its appearance at the Tokyo Auto Salon. With a newly designed flat roof carrier, large mud flaps with rally-inspired straps, and a stainless-steel rear under cover for a rugged look, this model brings out the full robustness of the Delica D:5. Delica Mini Wild Adventure style Also equipped with genuine accessories, this customized Delica Mini showcases camouflage‑pattern decals, a dedicated roof rack and mud flaps that create a tough, adventurous look. In line with the Delica D:5 Wild Adventure style, it features exclusive exterior accessories in special colors, creating a unique edition for this year’s exhibition. Delica Mini TOMICA 55th Anniversary Edition This rally‑inspired Delica Mini was created as part of TOMICA’s 55th Anniversary Auto Manufacturer Collaboration Project, celebrating the legacy of Japan’s beloved die‑cast miniature car brand. Its energetic graphics evoke smoke rising from magma‑like red tones, flowing from the front of the vehicle to the sides. To mark this milestone, the special 55th Anniversary logo appears as a rally plate, while the iconic TOMICA logo is styled like sponsor decals — giving the car an authentic rally aesthetic.Triton rally car - AXCR 2025 ChampionBased on the Triton pickup truck, this AXCR 2025 competition vehicle has been enhanced through weight reduction, suspension tuning, and improvements to engine performance and durability to withstand the extreme demands of cross‑country rallying. Driven by Chayapon Yotha and Peerapong Sombutwong, this Triton battled through eight days and approximately 2,300 kilometers of rugged terrain to reclaim the overall championship title for the first time in three years.Delica D:5 - AXCR 2025 support carLeveraging the Delica D:5’s inherent durability, handling, and off‑road capability, this vehicle served as a vital support car throughout the entire AXCR 2025 rally. The model on display is the actual vehicle driven by Team Director Hiroshi Masuoka during on‑site operations, navigating between start and finish points, mid‑stage service areas, and rugged course‑side terrain.Mitsubishi Motors’ special website for Tokyo Auto Salon 2026 (in Japanese only)https://www.mitsubishi-motors.co.jp/lineup/delica_custom/About Mitsubishi Motors Mitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society. For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Xforce Xforce Launch at Taipei Auto Show* TOKYO, Jan 6, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that China Motor Corporation (CMC), its production and sales partner in Taiwan, is scheduled to begin sales of the Xforce compact SUV in January. Manufactured at CMC’s Yangmei Plant, this launch marks the first time in nine years that Mitsubishi Motors has introduced a newly developed, locally produced model to the Taiwanese market.The Xforce is a five-seater compact SUV that was developed based on the concept "Best-suited buddy for an exciting life." Following its launch in Indonesia in November 2023, the Xforce was introduced to other ASEAN countries such as Vietnam and the Philippines, as well as Latin America, Africa, and the Middle East. As one of Mitsubishi Motors’ global strategic models, with cumulative sales of approximately 62,000 units, it has earned praise for its stylish yet robust SUV design, offering a spacious and comfortable five-passenger cabin while maintaining a maneuverable, compact body size.Produced locally in Taiwan by CMC for the Taiwanese market, this newly introduced Xforce meets the country’s Euro 6c emissions standards and offers distinctive features, including an integrated Level-2 equivalent advanced driver assistance system that combines Adaptive Cruise Control (ACC) and Lane Keep Assist (LKA) , a large 10.25-inch digital display, and a blue body color developed specifically for Taiwan.“We have developed a special version of the Xforce for the Taiwanese market, where we have worked alongside CMC for more than 60 years, to further strengthen our presence and enhance product value,“ said Tatsuo Nakamura, executive vice president of Mitsubishi Motors. ”After careful local research, we have created a model with greater value that we proudly stand behind. Reservations have already exceeded our initial projections, and we are truly excited to deliver this model to our customers in Taiwan.”*From left to right: Tatsuo Nakamura, executive vice president of Mitsubishi Motors; Hsin-Cheng Tseng, president at CMC.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) - a member of the Alliance with Renault and Nissan - is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification - launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society. For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., Jan 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, has been accepted by the National Medical Products Administration (NMPA) in China. If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population.Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(1) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(2) MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.comAbout LEQEMBI (generic name: lecanemab)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 52 countries and is under regulatory review in 8 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in the U.S., China, the UK, and others, and applications have been filed in 4 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A rolling Supplemental Biologics License Application (sBLA) for initiation treatment was initiated under Fast Track status in September 2025, and completed in November 2025. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In December 2025, Lecanemab has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases(NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co.,Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.For more details, please visit: https://www.eisai.com/news/2026/pdf/enews202601pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com